Xelucip Tablet contains Relugolix 120 mg, a potent oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. Relugolix acts by selectively inhibiting GnRH receptors in the pituitary gland, leading to a rapid and sustained suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. This results in a significant reduction in testosterone production, which is critical in managing hormone-sensitive prostate malignancies. Xelucip offers a convenient oral dosing regimen that provides effective androgen deprivation without the initial testosterone surge commonly associated with GnRH agonists, thereby minimizing the risk of clinical flare. The pharmacokinetic profile of Relugolix supports once-daily administration with consistent plasma concentrations. Clinical studies have demonstrated that Xelucip effectively lowers testosterone levels to castrate ranges within days, improving progression-free survival and symptom control in patients with advanced prostate cancer. It is generally well tolerated, with adverse effects including hot flushes, fatigue, and potential cardiovascular risks, necessitating careful patient monitoring. Xelucip should be prescribed and administered under the supervision of a qualified healthcare professional experienced in oncology and hormone therapy management.